Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Amazon Looks To Shrug Off Slowing E-Commerce Catalysts

By Josh Enomoto, InvestorPlace Contributor

Although the weakening of pandemic-related catalysts could slow e-commerce growth, AMZN stock is still worth believing in.

7 Overheated Stocks to Sell as Pandemic Concerns Rise

By Josh Enomoto, InvestorPlace Contributor

Although the market is firing on all cylinders again, it’s time to consider trimming risk exposure in these stocks to sell.

Meta Materials May Be Worth It — For the Right Investor

By Josh Enomoto, InvestorPlace Contributor

Prospective buyers should really perform their ‘DD’ before deciding if they want to buy MMAT stock. It's more than a meme but needs time.

7 Best ETFs To Buy Now if You’re Looking for Safety

By Josh Enomoto, InvestorPlace Contributor

With rising market valuations making many investors fearful of holding the bag, these best ETFs to buy now can help mitigate risk.

The Cryptocurrency Move to Proof of Stake Could Be Bad for Nvidia

By Josh Enomoto, InvestorPlace Contributor

A big driver for Nvidia's profits is crypto mining, but if the miners stop needing Nvidia's GPUs, NVDA stock might take a hit.

Why Naked-Short Selling Accusations May Not Help GameStop Stock Bulls

By Josh Enomoto, InvestorPlace Contributor

Although enthusiasm about a naked short squeeze is strong for GME stock, you may want to reconsider this thesis.

Is Ocugen Worth a Shot Because of the Worsening Pandemic?

By Josh Enomoto, InvestorPlace Contributor

While OCGN stock seems like a reasonable speculation based on the worsening Covid-19 crisis, it’s still a tough gamble.

Zomedica Stock Might Not Appeal To Millennials as Much as Some Hope

By Josh Enomoto, InvestorPlace Contributor

While the U.S. pet market is theoretically conducive for ZOM stock, you should consider the fine print before jumping onboard.

An Unbalanced Business Could Hurt SoFi Technologies

By Josh Enomoto, InvestorPlace Contributor

Although SOFI stock is undergirded by several relevant financial solutions, warranted skepticism clouds its bullish narrative.

Don’t Pin Your Hopes for Sundial on U.S. Legalization

By Josh Enomoto, InvestorPlace Contributor

No matter what you think about SNDL stock, it’s best to assume that U.S. cannabis laws will stay as is.

Load More